Axa
APLS

Axa’s Apellis Pharmaceuticals APLS Stock Holding History

Axa’s Portfolio APLS Stock Details APLS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-173,495
Closed -$15.8M – 1067
2023
Q2 		$15.8M Buy
173,495
+2,386
+1% +$206K 0.05% 327
2023
Q1 		$11.3M Buy
171,109
+25,405
+17% +$1.47M 0.04% 391
2022
Q4 		$7.53M Sell
145,704
-784
-0.5% -$41.6K 0.03% 501
2022
Q3 		$10M Buy
146,488
+68,183
+87% +$4.03M 0.04% 434
2022
Q2 		$3.54M Buy
+78,305
New +$3.57M 0.01% 654
2021
Q3 		– Sell
-41,321
Closed -$2.61M – 1227
2021
Q2 		$2.61M Sell
41,321
-3,140
-7% -$162K 0.01% 842
2021
Q1 		$1.91M Sell
44,461
-166,647
-79% -$7.88M 0.01% 859
2020
Q4 		$12.1M Buy
211,108
+21,681
+11% +$917K 0.04% 460
2020
Q3 		$5.71M Buy
189,427
+18,793
+11% +$561K 0.02% 589
2020
Q2 		$5.57M Buy
170,634
+10,143
+6% +$326K 0.02% 584
2020
Q1 		$4.3M Buy
160,491
+66,200
+70% +$2.35M 0.02% 557
2019
Q4 		$2.89M Buy
+94,291
New +$2.61M 0.01% 744

Other funds holding APLS

Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $904M AUM 737.04% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Axa's APLS Position: Q3 2023 in Review

Axa sold out of Apellis Pharmaceuticals (APLS) in Q3 2023, closing a stake of 173,495 shares — an estimated $15.8M sold.

Axa first reported a position in APLS in Q4 2019 and held it in 12 quarters. The position peaked at $15.8M in Q2 2023. 256 funds tracked by Wall St. Rank hold APLS as of Q3 2023.

  • Axa reported no remaining Apellis Pharmaceuticals position as of Q3 2023 after selling out during the quarter.
  • Axa sold 173,495 Apellis Pharmaceuticals shares in Q3 2023, an estimated $15.8M.
  • Axa first reported a position in Apellis Pharmaceuticals in Q4 2019 and held it in 12 quarters.
  • Axa's Apellis Pharmaceuticals position peaked at $15.8M in Q2 2023.
  • 256 funds tracked by Wall St. Rank held Apellis Pharmaceuticals as of Q3 2023.

Based on Axa's 13F filing for Q3 2023, filed 14 Nov 2023.